Jounce Therapeutics (JNCE) has an average rating of outperform and price targets ranging from $7 to $20, according to analysts polled by Capital IQ. (MT...
Shares of Jounce Therapeutics (JNCE) were down almost 19% in Wednesday afternoon trading after Baird downgraded the clinical-stage drugmaker's stock to...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
| Address | 780 Memorial Drive Cambridge, Massachusetts 02139 |
| Phone | +1.857.259.3840 |
| Number of Employees | 115 |
| Recent SEC Filing | 06/28/2022 4 |
| President, Chief Executive Officer & Director | Richard Murray |
| Chief Financial Officer & Treasurer | Kimberlee Cobleigh Drapkin |
| Chief Medical Officer | Elizabeth G. Trehu |
| Chief Scientific Officer | Dmitri Wiederschain |
| Price Open | $3.02 |
| Previous Close | $3.04 |
| 52 Week Range | $2.76 - 9.81 |
| Market Capitalization | $153.0 M |
| Shares Outstanding | 51.7 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/04/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.98 |
| Beta vs. S&P 500 | N/A |
| Revenue | $65.2 M |
| Net Profit Margin | -400.91% |
| Return on Equity | -43.16% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
